Following review of data from the phase 2 ARTISTRY-6 trial and previously announced results from the phase 3 ARTISTRY-7 trial, Mural will discontinue all clinical development of nemvaleukin With $144.

but kept working toward phase 2 data in mucosal melanoma. Tuesday, Mural reported the failure of one cohort of the potentially registrational melanoma trial. The biotech also looked at preliminary ...

Medically reviewed by Katlein Franca, MD Sunspots (also called age or liver spots) appear as flat brown spots on the skin.

single-arm trial evaluating nemvaleukin as a monotherapy in 92 patients with mucosal melanoma with a minimum follow-up of at least six months. A review of the topline data from this cohort showed ...

The collaboration’s initial focus will be on performing WGS and bioinformatic analysis on 30 sinonasal mucosal melanoma cases. Each case will include both tumor and germline samples, enabling ...

Immunotherapy among women with 2 types of genital tract melanoma, vulvar and vaginal melanoma, was associated with improved overall survival.

The Melanoma Research Foundation (MRF) is pleased to announce the official launch of its annual award-winning #GetNaked campaign in recognition of Melanoma Awareness Month this May.

Mural’s stock surged 134% following the 15 April announcement. The latest setback came from the Phase II ARTISTRY-6 study (NCT03861793) in patients with mucosal melanoma. Nemvaleukin, an interleukin-2 ...

ARTISTRY-6, cohort 2 is a phase 2, single-arm trial evaluating nemvaleukin as a monotherapy in 92 patients with mucosal melanoma with a minimum follow-up of at least six months. A review of the ...

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American ...